Category: Zacks Small Cap Research

1323334353655340 / 550 POSTS
By John Vandermosten, CFANASDAQ:RXIIREAD THE FULL RXII RESEARCH REPORTDuring the second quarter, RXi obtained additional financing to continue the development of its immuno-oncology program, provided readouts for Samcyprone and RXI-109 in retinal sca ...
By Steven Ralston, CFANASDAQ:MNGAREAD THE FULL MNGA RESEARCH REPORTMagneGas (NASDAQ:MNGA) produces, sells and distributes MagneGas2®, a hydrogen-based fuel synthesized through its proprietary, patented Plasma Arc Flow™ process. Currently, the largest ...
By David Bautz, PhDNASDAQ:OPNTREAD THE FULL OPNT RESEARCH REPORTBusiness UpdateAcquisition of Adapt Pharma® Validates Opioid Overdose Treatment MarketOn August 28, 2018, Emergent Biosciences Inc. announced the acquisition of Adapt Pharma® for $635 mi ...
By John Vandermosten, CFANASDAQ:LPCNREAD THE FULL LPCN RESEARCH REPORTLipocine (NASDAQ:LPCN) filed its 2Q:18 10-Q and posted its earnings release on August 7, 2018 reporting net loss per share of ($0.15). These results were better than our forecast d ...
By John Vandermosten, CFANASDAQ:CORV READ THE FULL CORV RESEARCH REPORT2Q:18 Operational and Financial ResultsSince our last report, Brinavess has been on a roll. Enrollment was completed in the European Phase IV SPECTRUM study and data is expected b ...
By John Vandermosten, CFANASDAQ:AZRXREAD THE FULL AZRX RESEARCH REPORTAzurRx BioPharma, Inc. (NASDAQ:AZRX) filed their 2Q:18 10-Q on August 13th providing a financial update on the company’s performance. The company’s most important announcement year ...
By David Bautz, PhDNASDAQ:TNXPREAD THE FULL TNXP RESEARCH REPORTBusiness UpdateHONOR Data and Retrospective Analyses PresentedOn August 21, 2018, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced a poster presentation at the 2018 Military H ...
By John Vandermosten, CFANASDAQ:ATXIREAD THE FULL ATXI RESEARCH REPORTAvenue Therapeutics (NASDAQ:ATXI) provided their press release and their form 10-K including second quarter 2018 financial results for investor review. Total expenses for the secon ...
By Brian Marckx, CFANASDAQ:VIVEREAD THE FULL VIVE RESEARCH REPORTQ2 Results: Sales Force Realignment Appears To Be Paying Dividends As U.S. Systems Sales Crush Prior Record…Viveve (VIVE) reported Q2 2018 financial results and provided a business upda ...
By John Vandermosten, CFANASDAQ:ATRSREAD THE FULL ATRS RESEARCH REPORTFDA Approval of Teva Generic Epinephrine PenOn August 16, 2018 the FDA granted approval of Teva’s (NYSE:TEVA) epinephrine auto-injector for severe allergies. Both the 0.3 mg and th ...
1323334353655340 / 550 POSTS